Codexis (CDXS) Shares Outstanding (Diluted Average) (2014 - 2026)
Codexis (CDXS) recorded quarterly Shares Outstanding (Diluted Average) of $90.8 million in Q1 2026, up 4.16% quarter-over-quarter from $87.1 million in Q4 2025, and up 10.14% on a YoY basis from $82.4 million in Q1 2025.
Codexis (CDXS) Shares Outstanding (Diluted Average) (2014 - 2026) Analysis & Trends
Codexis' Shares Outstanding (Diluted Average) history runs 13 years deep, the most recent figure standing at $90.8 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 10.14% year-over-year to $90.8 million; the TTM figure through Mar 2026 stood at $90.8 million (up 10.14% YoY), while the FY2025 annual figure was $87.1 million, up 18.71% from the prior year.
- Shares Outstanding (Diluted Average) was $90.8 million for Q1 2026 at Codexis, up from $87.1 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $90.8 million in Q1 2026 to a low of $65.1 million in Q1 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $73.4 million across 5 years, with a median of $69.9 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Diluted Average) declined 3.65% in 2022, then grew 21.78% in 2025.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $65.3 million in 2022, then gained by 4.27% to $68.1 million in 2023, then grew by 7.75% to $73.4 million in 2024, then grew by 18.71% to $87.1 million in 2025, then increased by 4.16% to $90.8 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $90.8 million (Q1 2026), $87.1 million (Q4 2025), and $86.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 92.44 Mn |
| 10 | Codexis | 226.01 Mn | 160.87 Mn | 13.18 Mn | 90.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 90.77 Mn |
| Dec 31, 2025 | 87.14 Mn |
| Sep 30, 2025 | 86.05 Mn |
| Jun 30, 2025 | 85.39 Mn |
| Mar 31, 2025 | 82.41 Mn |
| Dec 31, 2024 | 73.41 Mn |
| Sep 30, 2024 | 72.03 Mn |
| Jun 30, 2024 | 70.12 Mn |
| Mar 31, 2024 | 69.85 Mn |
| Dec 31, 2023 | 68.13 Mn |
| Sep 30, 2023 | 67.67 Mn |
| Jun 30, 2023 | 67.57 Mn |
| Mar 31, 2023 | 65.93 Mn |
| Dec 31, 2022 | 65.34 Mn |
| Sep 30, 2022 | 65.27 Mn |
| Jun 30, 2022 | 65.29 Mn |
| Mar 31, 2022 | 65.10 Mn |
| Dec 31, 2021 | 64.57 Mn |
| Sep 30, 2021 | 67.74 Mn |
| Jun 30, 2021 | 64.43 Mn |